Effect of HPV Vaccination on Women Aged 25 Years
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02296255|
Recruitment Status : Completed
First Posted : November 20, 2014
Last Update Posted : November 20, 2014
|Condition or disease||Intervention/treatment||Phase|
|Cervical Cancer||Biological: Cervarix®, GlaxoSmithKline||Phase 4|
The present trial, funded by Istituto Toscano Tumori, started in 2010 and was directed to all women aged 25 (birth cohorts 1985 and 1986), resident in the province of Florence and targeted by the screening program. After receiving approval from the Ethics Committee of the Local Health Unit of Florence, women were invited by invitation letter containing a clear description of the study. All women complying with the invitation were asked to fill in the informed consent document.
Women were randomized 1:2 in the Experimental Arm or in the Control Arm. At enrollment, women in the Experimental Arm, after collection of cervical samples (for Pap-test and HPV test), blood sample (for HPV antibody testing on serum before vaccination) and one first void urine sample (for HPV testing), received free vaccination with Cervarix® (vaccine against HPV 16 and 18, 3 doses scheduled). Women in the Control Arm received usual care, i.e. the collection of cervical sample for Pap test.
All women who signed the informed consent have been enrolled regardless of being sexually active or not. For virgo women cervical sample was not collected.
At the second round of screening (30 months since enrollment), women in both Arms were asked to collect cervical samples (for Pap-test and HPV test) while a new blood sample for HPV antibody testing was collected only in women enrolled in the Experimental Arm.
Women with normal cytology in Control Arm and women with HPV-negative result and normal cytology in Experimental Arm, received a recommendation by mail to repeat screening test after 3 years. Women with abnormal Pap test (Atypical Squamous Cells of Undetermined Significance or more severe, ASC-US+) were referred to immediate colposcopy at the Cancer Prevention and Research Insitute. Women with normal cytology and HPV positive were called after one year to repeat HPV test and Pap test. If HPV and Pap test were negative, women repeated both test after 30 months from enrolment. Otherwise if HPV test remained positive and/or cytology abnormalities were detected women were referred for colposcopy: if colposcopy didn't reveal high grade lesions (≤ CIN2) women repeated HPV and Pap test after 30 months from enrollment, if colposcopy revealed final histological diagnosis of CIN2+ lesions, women were recommended for an excisional treatment (both for study and control group).
The presence of high risk (HR) HPVs was evaluated by Hybrid Capture 2 (Qiagen, Gaithersburg, USA) using probe B for the detection of 12 high risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 (Group 1) and 1 "probably carcinogenic to humans" type HPV 68 (Group 2).
HPV genotyping was performed by INNO-LiPA Genotyping Extra that allows the identification of 28 different HPV types on L1 region on the HPV genome, it identifies all known HPV high-risk types (Group 1) 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59; "probably carcinogenic to humans" (Group 2A) HPV68; and all "possibly carcinogenic" HPV 26, 53, 66, 69, 70, 73, 82 (Group 2B) and "not classified as to its carcinogenicity to humans" (Group 3) (6, 11); and other HPV types: 40, 43, 44, 54, 71, 74.
HPV antibody testing was performed on an established and validated HPV serology method based on Luminex technology heparin coating of the beads and pseudovirions (PsVs) of 17 HPV types belonging to alpha species: 3, 6, 11, 16, 18, 31, 32 ,33, 35, 39, 45, 52, 56, 58, 59, 68, 73, and for four HPV types belonging to beta species: 5, 15, 38, 76.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||832 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effective Surveillance and Impact of HPV Vaccination on Screening for Cervical Cancer in Tuscany|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||May 2011|
|Actual Study Completion Date :||July 2013|
No Intervention: no HPV vaccine
No delivery of HPV vaccine
Experimental: HPV vaccine (Cervarix®, GlaxoSmithKline)
Delivery of HPV vaccine (Cervarix®, GlaxoSmithKline) at 0, 1, 6 months
Biological: Cervarix®, GlaxoSmithKline
3 doses (0,1,6 months) of Cervarix®, GlaxoSmithKline
- number of HR-HPV infections and number of infections due to HPV vaccine types in cervical sample in the Experimental arm and in No intervention arm [ Time Frame: 30 months ]
- number of cytological abnormalities in the Experimental arm and in No intervention arm [ Time Frame: 30 months ]
- Number of subjects seropositive for HPV 16, 18, 31, 33, 35, 39, 45, 52, 56, 58, 59, 68 at enrollment [ Time Frame: enrollment ]
- Number of subjects seropositive for HPV16,18 31, 33, 35, 39, 45, 52, 56, 58, 59, 68 after vaccination [ Time Frame: 30 months ]
- Anti-HPV16,18 31, 33, 35, 39, 45, 52, 56, 58, 59, 68 Antibody Titers before vaccination [ Time Frame: at enrollment ]Titers are given as Mean Fluorescence Intensity Unit (MFI)
- Anti-HPV16,18 31, 33, 35, 39, 45, 52, 56, 58, 59, 68 Antibody Titers after vaccination [ Time Frame: 30 months ]Titers are given as Mean Fluorescence Intensity Unit (MFI)
- Number of participants reporting Adverse Events [ Time Frame: within 14 days following any injection ]Adverse Events assessed include Local pain, Local swelling, Local pruritus, Local Erythema, Fever, and every adverse event reported day by day in a diary
- HPV identification in urine samples [ Time Frame: at enrollment ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02296255
|Cancer Prevention and Research Institute, ISPO|
|Firenze, FI, Italy, 50139|
|Principal Investigator:||Francesca M Carozzi, PhD||Cancer Prevention and Research Institute|